Cargando…

WT1 Expression Levels Combined with Flow Cytometry Blast Counts for Risk Stratification of Acute Myeloid Leukemia and Myelodysplastic Syndromes

Wilm’s tumor 1 (WT1), a zinc-finger transcription factor and an epigenetic modifier, is frequently overexpressed in several hematologic disorders and solid tumors, and it has been proposed as diagnostic and prognostic marker of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). However...

Descripción completa

Detalles Bibliográficos
Autores principales: Giudice, Valentina, Gorrese, Marisa, Vitolo, Rosa, Bertolini, Angela, Marcucci, Rossella, Serio, Bianca, Guariglia, Roberto, Ferrara, Idalucia, Pepe, Rita, D’Alto, Francesca, Izzo, Barbara, Pedicini, Antonio, Montuori, Nunzia, Langella, Maddalena, Selleri, Carmine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067344/
https://www.ncbi.nlm.nih.gov/pubmed/33917307
http://dx.doi.org/10.3390/biomedicines9040387
_version_ 1783682781104046080
author Giudice, Valentina
Gorrese, Marisa
Vitolo, Rosa
Bertolini, Angela
Marcucci, Rossella
Serio, Bianca
Guariglia, Roberto
Ferrara, Idalucia
Pepe, Rita
D’Alto, Francesca
Izzo, Barbara
Pedicini, Antonio
Montuori, Nunzia
Langella, Maddalena
Selleri, Carmine
author_facet Giudice, Valentina
Gorrese, Marisa
Vitolo, Rosa
Bertolini, Angela
Marcucci, Rossella
Serio, Bianca
Guariglia, Roberto
Ferrara, Idalucia
Pepe, Rita
D’Alto, Francesca
Izzo, Barbara
Pedicini, Antonio
Montuori, Nunzia
Langella, Maddalena
Selleri, Carmine
author_sort Giudice, Valentina
collection PubMed
description Wilm’s tumor 1 (WT1), a zinc-finger transcription factor and an epigenetic modifier, is frequently overexpressed in several hematologic disorders and solid tumors, and it has been proposed as diagnostic and prognostic marker of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). However, the exact role of WT1 in leukemogenesis and disease progression remains unclear. In this real-world evidence retrospective study, we investigated prognostic role of WT1-mRNA expression levels in AML and MDS patients and correlations with complete blood counts, flow cytometry counts, and molecular features. A total of 71 patients (AML, n = 46; and MDS, n = 25) were included in this study, and WT1 levels were assessed at diagnosis, during treatment and follow-up. We showed that WT1 expression levels were inversely correlated with normal hemopoiesis in both AML and MDS, and positively associated with blast counts. Flow cytometry was more sensitive and specific in distinguishing normal myeloid cells from neoplastic counterpart even just using linear parameters and CD45 expression. Moreover, we showed that a simple integrated approach combining blast counts by flow cytometry, FLT3 mutational status, and WT1 expression levels might be a useful tool for a better prognostic definition in both AML and MDS patients.
format Online
Article
Text
id pubmed-8067344
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80673442021-04-25 WT1 Expression Levels Combined with Flow Cytometry Blast Counts for Risk Stratification of Acute Myeloid Leukemia and Myelodysplastic Syndromes Giudice, Valentina Gorrese, Marisa Vitolo, Rosa Bertolini, Angela Marcucci, Rossella Serio, Bianca Guariglia, Roberto Ferrara, Idalucia Pepe, Rita D’Alto, Francesca Izzo, Barbara Pedicini, Antonio Montuori, Nunzia Langella, Maddalena Selleri, Carmine Biomedicines Article Wilm’s tumor 1 (WT1), a zinc-finger transcription factor and an epigenetic modifier, is frequently overexpressed in several hematologic disorders and solid tumors, and it has been proposed as diagnostic and prognostic marker of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). However, the exact role of WT1 in leukemogenesis and disease progression remains unclear. In this real-world evidence retrospective study, we investigated prognostic role of WT1-mRNA expression levels in AML and MDS patients and correlations with complete blood counts, flow cytometry counts, and molecular features. A total of 71 patients (AML, n = 46; and MDS, n = 25) were included in this study, and WT1 levels were assessed at diagnosis, during treatment and follow-up. We showed that WT1 expression levels were inversely correlated with normal hemopoiesis in both AML and MDS, and positively associated with blast counts. Flow cytometry was more sensitive and specific in distinguishing normal myeloid cells from neoplastic counterpart even just using linear parameters and CD45 expression. Moreover, we showed that a simple integrated approach combining blast counts by flow cytometry, FLT3 mutational status, and WT1 expression levels might be a useful tool for a better prognostic definition in both AML and MDS patients. MDPI 2021-04-06 /pmc/articles/PMC8067344/ /pubmed/33917307 http://dx.doi.org/10.3390/biomedicines9040387 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Giudice, Valentina
Gorrese, Marisa
Vitolo, Rosa
Bertolini, Angela
Marcucci, Rossella
Serio, Bianca
Guariglia, Roberto
Ferrara, Idalucia
Pepe, Rita
D’Alto, Francesca
Izzo, Barbara
Pedicini, Antonio
Montuori, Nunzia
Langella, Maddalena
Selleri, Carmine
WT1 Expression Levels Combined with Flow Cytometry Blast Counts for Risk Stratification of Acute Myeloid Leukemia and Myelodysplastic Syndromes
title WT1 Expression Levels Combined with Flow Cytometry Blast Counts for Risk Stratification of Acute Myeloid Leukemia and Myelodysplastic Syndromes
title_full WT1 Expression Levels Combined with Flow Cytometry Blast Counts for Risk Stratification of Acute Myeloid Leukemia and Myelodysplastic Syndromes
title_fullStr WT1 Expression Levels Combined with Flow Cytometry Blast Counts for Risk Stratification of Acute Myeloid Leukemia and Myelodysplastic Syndromes
title_full_unstemmed WT1 Expression Levels Combined with Flow Cytometry Blast Counts for Risk Stratification of Acute Myeloid Leukemia and Myelodysplastic Syndromes
title_short WT1 Expression Levels Combined with Flow Cytometry Blast Counts for Risk Stratification of Acute Myeloid Leukemia and Myelodysplastic Syndromes
title_sort wt1 expression levels combined with flow cytometry blast counts for risk stratification of acute myeloid leukemia and myelodysplastic syndromes
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067344/
https://www.ncbi.nlm.nih.gov/pubmed/33917307
http://dx.doi.org/10.3390/biomedicines9040387
work_keys_str_mv AT giudicevalentina wt1expressionlevelscombinedwithflowcytometryblastcountsforriskstratificationofacutemyeloidleukemiaandmyelodysplasticsyndromes
AT gorresemarisa wt1expressionlevelscombinedwithflowcytometryblastcountsforriskstratificationofacutemyeloidleukemiaandmyelodysplasticsyndromes
AT vitolorosa wt1expressionlevelscombinedwithflowcytometryblastcountsforriskstratificationofacutemyeloidleukemiaandmyelodysplasticsyndromes
AT bertoliniangela wt1expressionlevelscombinedwithflowcytometryblastcountsforriskstratificationofacutemyeloidleukemiaandmyelodysplasticsyndromes
AT marcuccirossella wt1expressionlevelscombinedwithflowcytometryblastcountsforriskstratificationofacutemyeloidleukemiaandmyelodysplasticsyndromes
AT seriobianca wt1expressionlevelscombinedwithflowcytometryblastcountsforriskstratificationofacutemyeloidleukemiaandmyelodysplasticsyndromes
AT guarigliaroberto wt1expressionlevelscombinedwithflowcytometryblastcountsforriskstratificationofacutemyeloidleukemiaandmyelodysplasticsyndromes
AT ferraraidalucia wt1expressionlevelscombinedwithflowcytometryblastcountsforriskstratificationofacutemyeloidleukemiaandmyelodysplasticsyndromes
AT peperita wt1expressionlevelscombinedwithflowcytometryblastcountsforriskstratificationofacutemyeloidleukemiaandmyelodysplasticsyndromes
AT daltofrancesca wt1expressionlevelscombinedwithflowcytometryblastcountsforriskstratificationofacutemyeloidleukemiaandmyelodysplasticsyndromes
AT izzobarbara wt1expressionlevelscombinedwithflowcytometryblastcountsforriskstratificationofacutemyeloidleukemiaandmyelodysplasticsyndromes
AT pediciniantonio wt1expressionlevelscombinedwithflowcytometryblastcountsforriskstratificationofacutemyeloidleukemiaandmyelodysplasticsyndromes
AT montuorinunzia wt1expressionlevelscombinedwithflowcytometryblastcountsforriskstratificationofacutemyeloidleukemiaandmyelodysplasticsyndromes
AT langellamaddalena wt1expressionlevelscombinedwithflowcytometryblastcountsforriskstratificationofacutemyeloidleukemiaandmyelodysplasticsyndromes
AT sellericarmine wt1expressionlevelscombinedwithflowcytometryblastcountsforriskstratificationofacutemyeloidleukemiaandmyelodysplasticsyndromes